Please login to the form below

Not currently logged in
Email:
Password:

squamous cell cancer

This page shows the latest squamous cell cancer news and features for those working in and with pharma, biotech and healthcare.

New data could put Roche’s Tecentriq first in squamous lung cancer

New data could put Roche’s Tecentriq first in squamous lung cancer

small cell lung cancer (NSCLC) reduced the risk of disease worsening or death compared to chemotherapy alone. ... Squamous non-small cell lung cancer is difficult to treat and there have been limited new treatment options over the last few decades,

Latest news

  • Data backs up Roche’s Tecentriq/Avastin combo in lung cancer Data backs up Roche’s Tecentriq/Avastin combo in lung cancer

    Giving Tecentriq (atezolizumab) and Avastin (bevacizumab) on top of chemotherapy to previously-untreated patients with advanced non-squamous non-small-cell lung cancer (NSCLC) resulted in a 38% reduction in PFS ... group of people with advanced

  • Merck pulls Keytruda filing in Europe, despite US approval Merck pulls Keytruda filing in Europe, despite US approval

    EU regulators don’t seem to be as comfortable with Merck &Co’s data on Keytruda as a first-line treatment for non-squamous non-small cell lung cancer (NSCLC) as ... The decision shows that EU regulators are not happy to approve new cancer drugs based

  • NICE expands Merck KGaA’s Erbitux reach NICE expands Merck KGaA’s Erbitux reach

    After several attempts, Merck KgAa has finally persuaded the UK medicines cost-effectiveness watchdog to back its monoclonal antibody Erbitux (cetuximab), for use in patients with recurrent or metastatic squamous cell ... All eyes are now on BMS, who is

  • Lilly wins on appeal in Alimta vitamin regimen dispute Lilly wins on appeal in Alimta vitamin regimen dispute

    The UK Supreme Court has ruled in favour of Eli Lilly in a long-running patent dispute with Actavis relating to its big-selling cancer drug Alimta. ... to treat non-squamous non-small cell lung cancer (NSCLC) and is Lilly's third-biggest product.

  • Keytruda is first FDA-approved drug for molecular indication Keytruda is first FDA-approved drug for molecular indication

    The cancer drug has become the first to be approved by the FDA to treat all cancers with a specific tumour biomarker. ... The drug has previously picked up approvals in melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell cancer and

More from news
Approximately 0 fully matching, plus 48 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Therapy Watch expands oncology and IBD portfolios

    Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer ... PCa), Renal Cell Carcinoma (RCC) and

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics